January 10, 2022 5:09pm

Well, I was right in some sense as more sector equities moved beyond 52-week lows along with the IBB and XBI

Pre-open Indication results: 6 HITs and 5 MISS

JPMorgan News Flow: Regenxbio (RGNX), Ultragenyx Pharmaceuticals (RARE), Solid Biosciences (SLDB), Fate Therapeutics (FATE), MiMedx (MDXG), BioLife Solutions (BLFS), Editas Medicine (EDIT), AxoGen (AXGN), Alnylam Pharmaceuticals (ALNY) and Pluristem (PSTI) <press releases and PdFs - see below>

If I have learned one thing as a former research analyst, venture and public markets investor then a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

The Dow closed DOWN -162.79 points (-0.45%); the S&P closed DOWN -6.74 points (-0.14%) while the Nasdaq closed UP +6.93 points (+0.05%)



Sector equities fell on Monday, extending a rocky start to 2022 as interest rates rise and the JPMorgan Healthcare Conference begins virtually.

The rough start to the year for stocks has come as interest rates have spiked. The Nasdaq is now down more than 6% for the year and at one point on Monday was more than 10% below its intraday record high from November.

The sell-off was broader than just “our” stem, cell and gene therapy sector, it also included tech, with roughly 70% of S&P 500 stocks declining.

Biggest “tankers” were Regenxbio (RGNX), ReNeuron (RENE.L), Ultragenyx Pharmaceuticals (RARE) and Intellia Therapeutics (NTLA) while increasing “poppers” were Vericel (VCEL), Alnylam Pharmaceuticals, CRISPR Therapeutics (CRSP), (ALNY) BioLife Solutions (BLFS).

“Pumping and promoting” away was Biostage (BSTG) which jumped to $3.23 with 1,760 shares traded early in the session then dropping -$0.03 with 2,076 shares traded sliding to $2.33.


RegMed Investors’ (RMi) pre-open: “it’ time to take a few risks to make us smile about our portfolios. Out on a limb and possibly early, I still want to BUY the 52-week lows; there’s risk in the cards and volatility in the pot” …  https://www.regmedinvestors.com/articles/12249


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Monday opened negative at 2 up/31 downs, 1 flat and 1 acquired, stayed negative at the mid-day at 8/25, 1 flat and 1 acquired, ending with a neutral close of 16/16, 2 flats, and 1 acquired;


Pre-open indication results: 6 Hits < Biostage (OTCQB: BSTG -$0.03), Alnylam Pharmaceuticals (ALNY +$2.03), CRISPR Therapeutics (CRSP +$1.43), Editas Medicine (EDIT +$0.56), Global Blood Therapeutics (GBT +$0.54), Vericel (VCEL +$2.46)> 5 MISS < Adverum Biotechnologies (ADVM -$0.04), Applied Genetic Technologies (AGTC -$0.04), Sangamo Therapeutics (SGMO -$0.14), Athersys (ATHX -$0.0027), Cellectis SA (CLLS +$0.20)    


Note: Gene editing is the next phase of genetic medicine, and another big step was just announced. Monday morning, Pfizer (PFE) unveiled a $1.3 billion partnership with Beam Therapeutics to develop three treatments for genetic disease in the next four years. They’ll use BEAM’s leading-edge technology that makes precise corrections to typographical errors in our genes—a technology called “base editing”. <Barron’s>


52-week Lows:

IBB hit a 52-week low of 138.42

XBI hit a 52-week low of 101.43

Applied Genetic Technologies (AGTC) hit a 52-week low of $1.73

Verastem (VSTM) hit a 52-week low of $1.83

Solid Biosciences (SLDB) hit a 52-week low of $1.53

Adverum Biosciences (ADVM) hit a 52-week low of $1.64

uniQure NV (QURE) hit a 52-week low of $18.71

CRISPR Therapeutics (CRSP) hit a 52-week low of $65.21

Homology Medicine (FIXX) hit a 52-week low of $3.44

Precigen (PGEN) hit a 52-week low of $3.11

Ultragenyx (RARE) hit a 52-week low of $71.86


Key Metrics:

  • Monday - Sector volume was HIGHER with 9 of the 16-upside having higher than the 3-month average volume with HIGHER volume of 11 of 16-downside having higher than the 3-month average volume;
  • Pluristem (PSTI) with 55.183 M versus the 3-month 227.25 K

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday the IBB closed up +1.15% and XBI closed up +0.20%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +0.61 points or +3.25% at 19.37



Jumping with share pricing momentum (10 of 16):

  • Vericel (VCEL +$2.46),
  • Alnylam Pharmaceuticals (ALNY +$2.03),
  • CRISPR Therapeutics (CRSP +$1.43),
  • BioLife Solutions (BLFS +$1.27),
  • Fate Therapeutics (FATE +$1.00),
  • Editas Medicine (EDIT +$0.56),
  • Global Blood Therapeutics (GBT +$0.54),
  • Pluristem (PSTI +$0.36),
  • Cellectis SA (CLLS +$0.20),
  • Homology Medicine (FIXX +$0.19),

Hammered in today’s market (10 of 16):

  • ReNeuron (RENE.L -$2.00),
  • Intellia Therapeutics (NTLA -$1.51),
  • Regenxbio (RGNX -$0.93),
  • Ultragenyx (RARE -$0.69),
  • AxoGen (AXGN -$0.34),
  • Chinook Therapeutics (KDNY -$0.26),
  • MiMedx (MDXG -$0.16
  • bluebird bio (BLUE -$0.14),
  • Sangamo Therapeutics (SGMO -$0.14),
  • Solid Biosciences (SLDB-$0.05),


  • 2- uniQure NV (QURE)), Verastem (VSTM) and 1 - Stemline Therapeutics (STML) – acquired


January, Q1/2022:

  • Monday (1/10) closed neutral with 16 incliners, 16 decliners, 2 flats and 1 acquired
  • Friday closed negative with 7 incliners, 26 decliners, 1 flat and 1 acquired
  • Thursday closed negative with 8 incliners, 22 decliners, 4 flats and 1 acquired
  • Wednesday closed negative with 4 incliners, 30 decliners and 1 acquired
  • Tuesday closed negative with 5 incliners, 29 decliners and 1 acquired
  • Monday (1/3) closed positive with 32 incliners, 0 decliners and 1 acquired


JPMorgan Healthcare Conference News Flow:

Regenxbio (RGNX),

Ultragenyx Pharmaceuticals (RARE),

Solid Biosciences (SLDB),

Fate Therapeutics (FATE),

MiMedx (MDXG),

BioLife Solutions (BLFS),

Editas Medicine (EDIT),

AxoGen (AXGN),

Alnylam Pharmaceuticals (ALNY) and

Pluristem (PSTI)


The BOTTOM LINE: Some things seemed to work, Monday … I actually went with my personal feelings  AGAIN and respond to the hope of sector breadth.

A few 52-week lows were bought today – maybe, I was a “hair” early on some but, it reinforces my probabilities which facilitated my predictive processes.

it was a count cards move or was it?

Algorithms, hedge funds and traders continue to punish the cell and gene therapy stocks as valuations “creeped” up.

  • Early January 2022 can deliver some gains but also generate algorithmic based losses.

Reiterating from last year, 2021, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.